Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders

A new gene signature associated with disulfidptosis that forecasts myasthenia gravis and suggests infiltration of immune microenvironment in thymoma patients

“…Currently, there is still a lack of complete comprehension regarding the pathological and physiological mechanisms that underpin TAMG. Further research is needed to explore the specific mechanisms behind thymoma, as numerous studies have indicated its association with immune system abnormalities and their impact on the immune system's recognition of self-antigens [ 10 , 32 ]. Furthermore, TAMG could potentially be linked to other elements like irregularities in neurotransmitters and harm to the neuromuscular junction.…”

“…Thymic cancers are linked to disturbed structure of the thymus and decreased or missing presence of MHC class II and AIRE factor. The outcome of this is expected to lead to the unsuccessful process of selecting both positive and negative thymocytes or a decrease in the generation of regulatory T cells [ 10 ]. In this research, we discovered that there were variations in both the quantity and performance of B lymphocytes among the high- and low-risk categories.…”

“…Currently, the precise understanding of TAMG remains uncertain, although scientists theorize that either the tumor cells or the atypical immune cells in the thymus gland might initiate an immune reaction against AChR or other elements of the neuromuscular junction [ [9] , [10] , [11] ]. The overexpression of specific genes has been linked to TAMG, and the reduced expression of CTLA-4 in thymoma could potentially heighten the vulnerability to developing MG [ 12 , 13 ].…”

The PNS Nurse Program

“…The extensive development of immunomodulatory therapies now offers increased possibilities for treating rare neurologic disorders with PNS involvement. 4 , 5 However, the complexity of these treatments and the severity of the conditions necessitate an interdisciplinary and patient-centered care network. In the case of diagnosing or treating rare diseases, specialized centers are typically the only facilities equipped to perform comprehensive procedures, which unfortunately leads to unnecessarily prolonged diagnosis times.…”

Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis

“…MG is caused by autoantibodies directed at proteins of the neuromuscular junction, primarily the acetylcholine receptor (AChR), resulting in neuromuscular transmission failure. 38 Several studies suggest that complement activation is the primary effector mechanism in patients with MG and MG animal models. 39 , 40 The administration of antibodies against C5 or C5-specific inhibitors has been shown to reduce the severity of MG in animal models.…”